EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer

Hua Yuan iD, Lin Xiu iD, Ning Li iD, Yifan Li iD, Lingying Wu iD, Hongwen Yao iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e51 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Hua Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical S…. Hauptthemen laut MEDLINE: Germ-Line Mutation, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The aim of this study was to determine the poly (ADP-ribose) polymerase inhibitors (PARPis) response and outcome of ovarian cancer (OC) patients with BRCA1/2 germline mutation and a history of breast cancer (BC). METHODS: Thirty-nine OC patients with BRCA1/2 germline mutation and a history of BC were included. The clinicopathological characteristics, PARPis response and prognosis were analyzed. RESULTS: The median interval from BC to OC diagnosis was 115.3 months (range=6.4-310.1). A total of 38 patients (38/39, 97.4%) received platinum-based chemotherapy after surgical removal. The majority of these patients were reported to be platinum sensitive (92.1%, 35/38). 21 patients (53.8%) received PARPis treatment with 16 patients (76.2%) for maintenance treatment and 5 patients (5/21, 23.8%) for salvage treatment. The median duration for PARPis maintenance and salvage treatment was 14.9 months (range=2.0-56.9) and 8.2 months (range=5.2-20.7), respectively. In the entire cohort, 5-year progression-free survival (PFS) and overall survival (OS) rate was 33.1% and 78.9%, respectively. Patients with BRCA1 mutation had a non-significantly worse 5-year PFS (28.6% vs. 45.8%, p=0.346) and 5-year OS (76.9% vs. 83.3%, p=0.426) than those with BRCA2 mutation. In patients with stage III-IV (n=31), first line PARPis maintenance treatment associated with a non-significantly better PFS (median PFS: NR vs. 22.4 months; 5-year PFS: 64.3% vs. 21.9%, p=0.096). CONCLUSION: The current study shows that these patients may have a good response to platinum-based chemotherapy and a favorable survival. And these patients can benefit from PARPis treatment and will likely be suitable candidates for PARPis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsBreast NeoplasmsBRCA1 ProteinBRCA2 ProteinHumansFemaleMiddle AgedAdultAgedSalvage TherapyRetrospective StudiesProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

BRCA1 GeneBRCA2 GeneBreast CancerOvarian CancerPARP InhibitorsPrognosis

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. absurgeonyao…

ORCID-Profile: Hua Yuan, Lin Xiu, Ning Li, Yifan Li, Lingying Wu, Hongwen Yao

Zitieren

APA

Yuan, H., Xiu, L., Li, N., Li, Y., Wu, L., & Yao, H. (2024). PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e51

Vancouver

Yuan H, Xiu L, Li N, Li Y, Wu L, Yao H. PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e51

BibTeX
@article{Yuan2024,
  author = {Yuan, Hua and Xiu, Lin and Li, Ning and Li, Yifan and Wu, Lingying and Yao, Hongwen},
  title = {PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e51}
}
Kostenlos starten →